GNH USA

Europe — EMA

Imipenem/Cilastatin (Cilastatin Sodium, Imipenem Monohydrate)

GNH USA supplies Imipenem/Cilastatin (Imipenem and Cilastatin), a carbapenem antibiotic for complicated intra‑abdominal, urinary and respiratory infections.

Cilastatin Sodium, Imipenem Monohydrate

Request sourcing

1
Pack/s

What is Cilastatin Sodium, Imipenem Monohydrate?

Imipenem and Cilastatin, the active ingredients in Imipenem/Cilastatin, are a carbapenem antibiotic combined with a renal dehydropeptidase inhibitor presented as an intravenous formulation for hospital use. It treats a broad range of serious bacterial infections in adult and pediatric patients.

GNH USA supplies Imipenem/Cilastatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

What is Cilastatin Sodium, Imipenem Monohydrate used for?

Imipenem/Cilastatin is employed for severe bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides effective bacterial clearance in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: eradicates resistant uropathogens in complicated cases. - Skin and soft‑tissue infections: treats deep or extensive infections caused by susceptible organisms. - Community‑acquired and hospital‑acquired pneumonia: covers a wide spectrum of respiratory pathogens. - Severe sepsis and septic shock: delivers rapid bactericidal activity in critically ill patients.

What are the side effects of Cilastatin Sodium, Imipenem Monohydrate?

Adverse reactions may occur with any intravenous antibiotic and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limited. - Rash: skin erythema or mild pruritus.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated colitis that can be life‑threatening.

What precautions apply to Cilastatin Sodium, Imipenem Monohydrate?

Use of Imipenem/Cilastatin requires careful clinical assessment.

- Renal function: adjust dosing in patients with impaired clearance. - Seizure risk: monitor individuals with a history of seizures or CNS disease. - Allergy: avoid in patients with known hypersensitivity to carbapenems. - Drug interactions: review concomitant medications that may lower seizure threshold. - Pregnancy and lactation: prescribe only when the potential benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Cilastatin Sodium, Imipenem Monohydrate interact with?

Imipenem/Cilastatin can interact with several drug classes.

Major Interactions (Avoid): - Valproic acid: may increase risk of seizures. - Other carbapenems: concurrent use can lead to additive toxicity. - Probenecid: may raise plasma concentrations of imipenem. - CNS stimulants: can lower seizure threshold.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolyte balance. - Anticoagulants: watch for altered INR values. - Oral contraceptives: may reduce hormonal efficacy.

Frequently asked questions

What infections is Imipenem/Cilastatin used to treat?+
Imipenem/Cilastatin is indicated for serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, skin and soft‑tissue infections, community‑acquired and hospital‑acquired pneumonia, and severe sepsis or septic shock. It is reserved for cases where broad‑spectrum coverage is required.
How does Imipenem work together with Cilastatin?+
Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to bacterial lysis. Cilastatin inhibits renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby increasing its plasma concentration and prolonging its antibacterial effect.
What is the usual dose of Imipenem/Cilastatin?+
The dosing regimen for Imipenem/Cilastatin is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and other clinical factors. Healthcare professionals should follow local guidelines and the product label.
Is Imipenem/Cilastatin safe during pregnancy or breastfeeding?+
Safety data for Imipenem/Cilastatin in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.
How do I order Imipenem/Cilastatin from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.
How does Imipenem/Cilastatin compare with other carbapenems?+
Imipenem/Cilastatin offers a broad spectrum of activity similar to other carbapenems but includes cilastatin to prevent renal degradation, resulting in higher and more stable plasma levels. This can provide a dosing advantage in patients with reduced renal function compared with carbapenems lacking a dehydropeptidase inhibitor.
What are the storage and handling requirements for Imipenem/Cilastatin?+
The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted for intravenous administration, it should be used promptly according to the manufacturer’s instructions and discarded if any discoloration or particulate matter appears.
How is Imipenem/Cilastatin administered?+
Imipenem/Cilastatin is administered intravenously by a healthcare professional. The solution is typically infused over a specified period, often 30 minutes, depending on the clinical protocol and patient tolerance. Administration should follow aseptic technique and institutional infusion guidelines.
What are the most serious risks associated with Imipenem/Cilastatin?+
The most serious adverse events include seizures, especially in patients with pre‑existing CNS disorders or renal impairment, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis, which can be life‑threatening and requires immediate medical attention.
Who should not receive Imipenem/Cilastatin?+
Patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem should not receive this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those taking medications that significantly lower the seizure threshold.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Cilastatin Sodium, Imipenem Monohydrate
Route
Intravenous Use
Manufacturer
Fresenius Kabi Deutschland Gmbh
Origin
EU

Related products

Andatin

Andatin

Cilastatin Sodium, Imipenem Monohydrate

Macure Pharma Aps
EU
Andatin

Andatin

Cilastatin Sodium, Imipenem Monohydrate

Macure Pharma Aps
EU
Andatin

Andatin

Cilastatin Sodium, Imipenem Monohydrate

Macure Pharma Aps
EU
Imipenem + Cilastatina Aurovitas

Imipenem + Cilastatina Aurovitas

Cilastatin Sodium, Imipenem Monohydrate

Eugia Pharma (Malta) Ltd
EU